MYOS RENS Technology Inc. (NASDAQ:MYOS) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

MYOS RENS Technology (NASDAQ:MYOS) opened at 1.47 on Wednesday. MYOS RENS Technology has a one year low of $1.02 and a one year high of $6.98. The stock has a 50 day moving average of $1.52 and a 200 day moving average of $2.18. The company’s market cap is $8.59 million.

COPYRIGHT VIOLATION WARNING: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at

About MYOS RENS Technology

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Receive News & Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related companies with's FREE daily email newsletter.